Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novoste

This article was originally published in The Gray Sheet

Executive Summary

Vascular brachytherapy device maker launches a third radiation source train for its Beta-Cath vascular radiation delivery system, the 60 mm in length, based on results of a 139-patient subset from the 1,098 patient RENO European registry. In this subset, the Beta-Cath reduced target vessel revascularization 75% versus the placebo group in the 94-patient LONG WRIST study. Average lesion length was 35.3 mm in RENO and 28 mm in LONG WRIST. Source trains of 30 mm and 40 mm also are available, in 5 Fr and 3.5 Fr diameters (1"The Gray Sheet" Feb. 18, 2002, In Brief)...

You may also be interested in...



Novoste Beta-Cath

Smaller 3.5 Fr version of the intravascular brachytherapy catheter gains PMA supplement approval, announced Feb. 13. The smallest diameter catheter commercially available, the device can be used with a 6 Fr guiding catheter, the firm says. The system will allow treatment of restenosis in vessels too small for the current 5 Fr system. Both are available with 30 mm and 40 mm radioactive source trains. The Beta-Cath is installed in 340 U.S. hospitals and controls about 85% of the U.S. brachytherapy market (1"The Gray Sheet" Feb. 4, 2002, p. 17)...

Breckenridge Eyes First Kyprolis Generic With FDA Approval

Towa’s US-based Breckenridge is aiming for exclusivity with its generic version of Amgen’s Kyprolis – developed with partner Natco Pharma – after obtaining one of the first approvals for several strengths of the treatment for relapsed or refractory multiple myeloma.

Nestlé Sees Importance Of Local Brands In ‘Fragmented’ VMS Market

As Nestlé continues to expand its presence in the VMS market it will not take a brand popular in one country and “force” that name on consumers in a different part of the world, says CEO Mark Schneider.

UsernamePublicRestriction

Register

MT016344

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel